Emergent BioSolutions Commends U.S. House of Representatives for Naloxone Accessibility Initiative

Emergent BioSolutions acknowledges the U.S. House for making naloxone available at AED locations to combat opioid overdoses.

Quiver AI Summary

Emergent BioSolutions Inc. has praised the U.S. House of Representatives for incorporating over-the-counter naloxone into Automated External Defibrillator (AED) locations in its buildings, which enhances access for first responders addressing opioid overdoses. This initiative, championed by Representative Buddy Carter, aims to combat the escalating public health crisis of opioid overdoses. Emergent continues to promote its naloxone products, including NARCAN® Nasal Spray and KLOXXADO® Nasal Spray, as critical tools for saving lives. The company has distributed over 85 million doses since 2016, further contributing to the reduction of overdose deaths as reported by the CDC. Emergent emphasizes the importance of having naloxone available, underscoring that opioid overdoses can occur unexpectedly.

Potential Positives

Emergent BioSolutions is being recognized for its contributions to public health by the U.S. House of Representatives for increasing access to naloxone, positioning the company as a leader in the fight against opioid overdoses.
The launch of NARCAN® Nasal Spray as the first over-the-counter opioid overdose reversal treatment highlights Emergent's commitment to making life-saving products widely accessible.
More than 85 million doses of NARCAN® have been distributed in the U.S. and Canada since 2016, demonstrating the effectiveness and necessity of their products in real-world scenarios.
Emergent's recognition of Representative Buddy Carter’s efforts underscores the company's engagement with key stakeholders and its dedication to addressing the opioid crisis as a significant public health concern.

Potential Negatives

The press release focuses mainly on a positive recognition from the U.S. House of Representatives, which may inadvertently highlight the company’s dependency on legislative actions to promote their products.
The detailed description of naloxone and its use includes warnings about serious side effects, which can raise concerns about the safety and administration of their products among potential users.
Emergent’s products are positioned within a critical public health crisis (opioid overdoses), which can lead to negative perceptions about the company's role in a widespread health issue rather than solely as a provider of solutions.

FAQ

What is the significance of naloxone being available in House AED locations?

This initiative provides immediate access to naloxone for managing opioid overdose emergencies in public buildings.

Who led the effort to add naloxone in the U.S. House of Representatives?

Representative Buddy Carter (R-GA) spearheaded the effort with support from his team and constituents.

How has Emergent BioSolutions contributed to naloxone distribution?

Emergent is a leading supplier, distributing over 85 million doses of NARCAN® since 2016 to combat opioid overdoses.

What is KLOXXADO® Nasal Spray?

KLOXXADO® Nasal Spray is a prescription medication used to treat opioid emergencies, including overdoses, in adults and children.

How can I learn more about emergency naloxone access?

Visit NARCANDirect® or Emergent's product websites, KLOXXADO.com and NARCAN.com, for information on naloxone access and training.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$EBS Insider Trading Activity

$EBS insiders have traded $EBS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:

NEAL FRANKLIN FOWLER sold 35,000 shares for an estimated $204,050
KATHRYN C ZOON sold 10,000 shares for an estimated $57,300
KEITH KATKIN sold 7,844 shares for an estimated $49,417

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$EBS Hedge Fund Activity

We have seen 83 institutional investors add shares of $EBS stock to their portfolio, and 72 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC added 1,020,582 shares (+68.9%) to their portfolio in Q1 2025, for an estimated $4,960,028
LSV ASSET MANAGEMENT added 809,591 shares (+3748.1%) to their portfolio in Q1 2025, for an estimated $3,934,612
INVESCO LTD. removed 791,948 shares (-51.4%) from their portfolio in Q1 2025, for an estimated $3,848,867
CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 706,959 shares (-54.8%) from their portfolio in Q1 2025, for an estimated $3,435,820
ACADIAN ASSET MANAGEMENT LLC added 631,794 shares (+313.5%) to their portfolio in Q1 2025, for an estimated $3,070,518
DIMENSIONAL FUND ADVISORS LP added 492,579 shares (+44.6%) to their portfolio in Q1 2025, for an estimated $2,393,933
TWO SIGMA INVESTMENTS, LP removed 449,966 shares (-53.1%) from their portfolio in Q1 2025, for an estimated $2,186,834

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$EBS Analyst Ratings

Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 04/01/2025

To track analyst ratings and price targets for $EBS, check out Quiver Quantitative's $EBS forecast page.

Full Release

GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this public health issue a priority.

Expanding access to potentially life-saving treatments is critical to saving more Americans and their families from an opioid overdose death. Emergent remains focused on saving lives through efforts to increase access, awareness and the availability of NARCAN ^® Nasal Spray 4 mg and KLOXXADO ^® Nasal Spray 8 mg. Emergent strives to engage with key stakeholders committed to reducing overdose deaths, as one death is one too many.

“The efforts of Representative Carter (R-GA) to make naloxone readily available in the U.S. House of Representatives are commendable, and we are pleased to recognize his work to help save a life during an opioid overdose emergency,” said Joe Papa, president and chief executive officer at Emergent. “We believe the over-the-counter availability of naloxone, including our product, NARCAN ^® Nasal Spray, has directly contributed to the reduction in overdose deaths reported by the U.S. Centers for Disease Control and Prevention. Measures like this reinforce the importance of having life-saving naloxone nearby as an opioid overdose can happen to anyone, anywhere and at any time.”

In 2023, Emergent launched NARCAN ^® Nasal Spray as the first OTC opioid overdose reversal treatment. With more than 85 million doses distributed in the U.S. and Canada since 2016, it is an important tool in helping save lives from opioid overdose, including those caused by fentanyl. Emergent is the leading U.S. supplier of nasal naloxone, and offers an expanded range of products to support public interest groups, workplaces/businesses, as well as patients, consumers and healthcare providers.

NARCAN ^® (naloxone HCl) Nasal Spray 4 mg (two-dose carton)
NARCAN ^® Nasal Spray Wall Unit Kit: includes wall unit cabinet with alarm, poster and wayfinder sign
KLOXXADO ^® (naloxone HCl) Nasal Spray 8 mg (two-dose carton)
Convenience Kits: includes medical grade components including: One hard case with internal pockets, one medical grade CPR mask, one pair of nitrile examination gloves

Visit NARCANDirect ^® or one of Emergent’s product sites, KLOXXADO.com and NARCAN.com to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone.

About NARCAN ^® Nasal Spray
NARCAN ^® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN ^® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.

Important Safety Information for KLOXXADO ^® (naloxone HCl) Nasal Spray 8 mg

What is KLOXXADO ^® Nasal Spray?

KLOXXADO ^® Nasal Spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose in adults and children with signs of breathing problems and severe sleepiness or not being able to respond.
KLOXXADO ^® Nasal Spray is to be given right away and does not take the place of emergency medical care.
Get emergency medical help right away after giving the first dose of KLOXXADO ^® Nasal Spray, even if the person wakes up.

What is the most important information I should know about KLOXXADO ^® Nasal Spray?
Get emergency medical help right away after giving the first dose of KLOXXADO ^® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO ^® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO ^® Nasal Spray and watch the person closely until emergency help is received.

The medicine in KLOXXADO ^® Nasal Spray is safe to use in people who are not taking opioids. KLOXXADO ^® Nasal Spray is not intended for self-administration.

What should I tell my healthcare provider (pharmacist or prescriber) before using KLOXXADO ^® Nasal Spray?
Before using KLOXXADO ^® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:

have heart problems
are pregnant or plan to become pregnant. Use of KLOXXADO ^® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO ^® Nasal Spray.
are breastfeeding or plan to breastfeed. It is not known if KLOXXADO ^® Nasal Spray passes into your breast milk.

What are the possible serious side effects of KLOXXADO ^® Nasal Spray?
KLOXXADO ^® Nasal Spray may cause sudden opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure.

In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes.

Who should not use KLOXXADO ^® Nasal Spray?
Do not use KLOXXADO ^® Nasal Spray if you are allergic to naloxone hydrochloride or
any of the ingredients in KLOXXADO ^® Nasal Spray.

What are the most common side effects of KLOXXADO ^® nasal spray?
The most common side effects of KLOXXADO ^® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint.

These are not all of the possible side effects of KLOXXADO ^® Nasal Spray. Please see full Prescribing Information , including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO ^® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects.

You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch . You can also contact Hikma Specialty USA Inc. at: [email protected] or call 1-877-845-0689 or 1-800-962-8364.

Trademarks and logos are the property of their respective owners.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn , X , Instagram , Apple Podcasts and Spotify .

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]

Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]